BL1332 Phase 2 Misses Primary Endpoint, Clouding Path to Phase 3
BLCO sits 42% above its 52-week low of $14.44.
Summary
Bausch + Lomb's Phase 2 BL1332 trial in 129 post-surgical patients failed to hit its primary endpoint. Both doses produced numerically greater pain relief than vehicle — LS mean differences of -11.5 and -9.0 — but neither reached statistical significance on the primary measure. The 0.30% dose was nominally significant at six hours and complete relief rates at that point were 14.0% and 14.6% versus 3.7% for vehicle, though these are secondary and exploratory findings, not confirmatory evidence. Adverse event rates were 6.0%, 13.7% and 14.8% for the 0.30%, 0.15% and vehicle arms, with no treatment-related or serious events reported. The company says it will discuss the results with the FDA and is still evaluating Phase 3 planning, with no commitment announced — so the program's future is unresolved. This lands with the stock near its 52-week high, leaving little room for a clinical setback.
At the time of this announcement, BLCO was trading at $20.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $14.44 to $21.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.